Toxoplasmosis Research Institute
Chicago, IL ·EIN 36-3812611 ·Grant funding profile from IRS 990 filings
Who funds Toxoplasmosis Research Institute?
Toxoplasmosis Research Institute is funded by 2 grantmakers, led by The Rayni Foundation Inc ($100K), Dunphy Family Foundation Inc ($500). In total, IRS Form 990 filings record $101K in grants to Toxoplasmosis Research Institute between 2020–2024.
| Funder | Total given | Grants | Years |
|---|---|---|---|
| The Rayni Foundation Inc | $100,000 | 1 | 2024 |
| Dunphy Family Foundation Inc | $500 | 2 | 2020–2022 |
What grants has Toxoplasmosis Research Institute received?
Individual grants from IRS Form 990 filings, newest first
| Year | Funder | Purpose | Amount |
|---|---|---|---|
| 2024 | The Rayni Foundation Inc | HEALTH RESEARCH | $100,000 |
| 2022 | Dunphy Family Foundation Inc | IN SUPPORT OF OPERATIONS | $200 |
| 2020 | Dunphy Family Foundation Inc | CHARITABLE | $300 |
Frequently Asked Questions
Who funds Toxoplasmosis Research Institute?
Toxoplasmosis Research Institute is funded by 2 grantmakers, led by The Rayni Foundation Inc ($100K), Dunphy Family Foundation Inc ($500). In total, IRS Form 990 filings record $101K in grants to Toxoplasmosis Research Institute between 2020–2024.
Who is Toxoplasmosis Research Institute's largest funder?
The Rayni Foundation Inc is the largest recorded funder of Toxoplasmosis Research Institute, with $100K across 1 grant (2024).
How much grant funding has Toxoplasmosis Research Institute received?
IRS 990 filings record $101K in grants to Toxoplasmosis Research Institute across 3 grants from 2 funders between 2020–2024. Filings are published on a delay, so recent grants may not appear yet.
Looking for funders like Toxoplasmosis Research Institute's?
Grantable's AI matches your organization against 200,000+ grantmakers — including every funder on this page — using their real giving history.
Grant data is drawn from IRS Form 990 filings via Grantable's GrantGraph™. Filings are published on a delay; recent grants may not appear yet.